Cardiol Therapeutics Inc.(CRDL)Earnings, Financials & Key Ratios
CRDL•NASDAQ
$1.30
$145M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.Show more
- Revenue$0
- EBITDA-$40M-80.0%
- Net Income-$37M-72.8%
- EPS (Diluted)-0.51-15.9%
- ROE-138.47%-117.8%
- Debt/Equity0.01+3.9%
CRDL Key Insights
Cardiol Therapeutics Inc. (CRDL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 82 (top 18%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 11.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRDL Price & Volume
Cardiol Therapeutics Inc. (CRDL) stock price & volume — 10-year historical chart
Loading chart...
CRDL Growth Metrics
Cardiol Therapeutics Inc. (CRDL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.9%
Return on Capital
10 Years-77.9%
5 Years-90.98%
3 Years-90.5%
Last Year-151.25%
CRDL Recent Earnings
Cardiol Therapeutics Inc. (CRDL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
Mar 30, 2026EPS
$0.05
Est $0.09
+43.4%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.09
Est $0.09
+0.0%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.07
Est $0.11
+36.4%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.10
Est $0.13
+23.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 30, 2026 | $0.05vs $0.09+43.4% | — |
| Q4 2025 | Nov 13, 2025 | $0.09vs $0.09+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.07vs $0.11+36.4% | — |
| Q2 2025 | May 13, 2025 | $0.10vs $0.13+23.1% | — |
Based on last 12 quarters of dataView full earnings history →
CRDL Peer Comparison
Cardiol Therapeutics Inc. (CRDL) competitors in Cannabis and cannabinoid product companies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 TELA | 44.38M | 1.10 | -0.83 | 18.56% | -50.61% | -272.13% | 1.51 | |
 MDGL | 12.27B | 534.86 | -41.62 | 432.05% | -27.32% | -50.15% | 0.59 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 ARDX | 1.71B | 6.98 | -26.85 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare CRDL vs Peers
Cardiol Therapeutics Inc. (CRDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRDL Income Statement
Cardiol Therapeutics Inc. (CRDL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 62.27K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | -100% | - | - | - |
| Cost of Goods Sold | 53.34K | 91.49K | 116.11K | 180.17K | 174.26K | 162.23K | 187.38K | 0 | 33.7K |
| COGS % of Revenue | - | - | - | - | 279.87% | - | - | - | - |
| Gross Profit | -53.34K▲ 0% | -91.49K▼ 71.5% | -116.11K▼ 26.9% | -180.17K▼ 55.2% | -112K▲ 37.8% | -162.23K▼ 44.8% | -187.38K▼ 15.5% | 0▲ 100.0% | -33.7K▲ 0% |
| Gross Margin % | - | - | - | - | -179.87% | - | - | - | - |
| Gross Profit Growth % | - | -71.52% | -26.91% | -55.17% | 37.84% | -44.85% | -15.51% | 100% | - |
| Operating Expenses | 1.6M | 7.49M | 10.78M | 16.06M | 30.46M | 30.33M | 22.29M | 40.28M | 33.19M |
| OpEx % of Revenue | - | - | - | - | 48912.58% | - | - | - | - |
| Selling, General & Admin | 1.1M | 5.87M | 8.06M | 7.81M | 21.86M | 16.34M | 11.55M | 26.26M | 18.9M |
| SG&A % of Revenue | - | - | - | - | 35110.47% | - | - | - | - |
| Research & Development | 441.26K | 1.53M | 2.72M | 8.25M | 8.59M | 13.99M | 10.73M | 14.01M | 14.21M |
| R&D % of Revenue | - | - | - | - | 13802.1% | - | - | - | - |
| Other Operating Expenses | -60.56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 76.01K |
| Operating Income | -1.59M▲ 0% | -7.39M▼ 365.0% | -10.89M▼ 47.4% | -16.24M▼ 49.1% | -30.57M▼ 88.2% | -30.49M▲ 0.2% | -22.47M▲ 26.3% | -40.28M▼ 79.2% | -33.23M▲ 0% |
| Operating Margin % | - | - | - | - | -49092.44% | - | - | - | - |
| Operating Income Growth % | - | -365.01% | -47.42% | -49.07% | -88.22% | 0.25% | 26.3% | -79.22% | - |
| EBITDA | -1.54M | -7.3M | -10.78M | -16.06M | -30.39M | -30.33M | -22.29M | -40.11M | -33.12M |
| EBITDA Margin % | - | - | - | - | -48812.58% | - | - | - | - |
| EBITDA Growth % | - | -375.2% | -47.67% | -49% | -89.25% | 0.21% | 26.53% | -80% | 2.31% |
| D&A (Non-Cash Add-back) | 53.34K | 91.49K | 116.11K | 180.17K | 174.26K | 162.23K | 187.38K | 162.1K | 109.7K |
| EBIT | -1.56M | -6.58M | -10.55M | -16.2M | -25.01M | -22.82M | -21.22M | -40.28M | -31.75M |
| Net Interest Income | -54.44K | -560.07K | 188.78K | 60.11K | 106K | 1.24M | 2.04M | 1.19M | 857.97K |
| Interest Income | 6.12K | 103.31K | 245.42K | 60.11K | 106K | 1.24M | 2.04M | 1.19M | 857.97K |
| Interest Expense | 60.56K | 663.37K | 621 | - | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -71.61K | -8.5M | 342.2K | 38.87K | 5.56M | 7.68M | 1.25M | 3.6M | 937.56K |
| Pretax Income | -1.66M▲ 0% | -15.89M▼ 856.9% | -10.55M▲ 33.6% | -16.2M▼ 53.5% | -25.01M▼ 54.4% | -22.82M▲ 8.8% | -21.22M▲ 7.0% | -36.68M▼ 72.8% | -32.29M▲ 0% |
| Pretax Margin % | - | - | - | - | -40170.87% | - | - | - | - |
| Income Tax | 60.56K | 663.37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -3.65% | -4.17% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.66M▲ 0% | -15.89M▼ 856.9% | -10.55M▲ 33.6% | -16.2M▼ 53.5% | -25.01M▼ 54.4% | -22.82M▲ 8.8% | -21.22M▲ 7.0% | -36.68M▼ 72.8% | -32.29M▲ 0% |
| Net Margin % | - | - | - | - | -40170.87% | - | - | - | - |
| Net Income Growth % | - | -856.92% | 33.61% | -53.53% | -54.39% | 8.78% | 6.99% | -72.82% | 0.61% |
| Net Income (Continuing) | -1.81M | -15.89M | -10.55M | -16.2M | -25.01M | -22.82M | -21.22M | -36.68M | -32.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.07▲ 0% | -0.66▼ 802.9% | -0.53▲ 19.7% | -0.69▼ 30.2% | -0.73▼ 5.8% | -0.49▲ 32.9% | -0.44▲ 10.2% | -0.51▼ 15.9% | -0.38▲ 0% |
| EPS Growth % | - | -802.87% | 19.7% | -30.19% | -5.8% | 32.88% | 10.2% | -15.91% | 17.9% |
| EPS (Basic) | -0.07 | -0.66 | -0.53 | -0.69 | -0.73 | -0.49 | -0.44 | -0.51 | - |
| Diluted Shares Outstanding | 22.71M | 24.2M | 25.82M | 29.86M | 43.22M | 62.51M | 64.46M | 71.57M | 84.73M |
| Basic Shares Outstanding | 22.71M | 24.2M | 25.82M | 29.86M | 43.22M | 62.51M | 64.46M | 71.57M | 84.73M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRDL Balance Sheet
Cardiol Therapeutics Inc. (CRDL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.48M | 24.03M | 14.37M | 14.95M | 87.14M | 45.32M | 36.15M | 31.67M | 12.81M |
| Cash & Short-Term Investments | 2.36M | 16.73M | 6.96M | 14.03M | 83.9M | 43.87M | 34.93M | 30.58M | 11.62M |
| Cash Only | 2.36M | 16.73M | 6.96M | 14.03M | 83.9M | 43.83M | 34.93M | 30.58M | 11.62M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 45.65K | 0 | 0 | 0 |
| Accounts Receivable | 101.75K | 460.78K | 0 | 0 | 65.74K | 354.24K | 0 | 361.62K | 195.88K |
| Days Sales Outstanding | - | - | - | - | 385.35 | - | - | - | - |
| Inventory | 0 | 6.35M | 6.2M | 357.02K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 25.31K | 19.5K | 723.27 | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 927.87K | 219.92K | 341.39K | 0 | 279.87K | 0 | 0 |
| Total Non-Current Assets | 735.83K | 658.13K | 1.13M | 943.24K | 735.74K | 435.64K | 547.42K | 195.59K | 140.98K |
| Property, Plant & Equipment | 18.81K | 25.55K | 584.05K | 479.55K | 356.49K | 218.16K | 337.06K | 195.59K | 140.98K |
| Fixed Asset Turnover | - | - | - | - | 0.17x | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 717.02K | 632.58K | 548.13K | 463.69K | 379.25K | 217.47K | 210.36K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 3.22M▲ 0% | 24.68M▲ 666.4% | 15.5M▼ 37.2% | 15.89M▲ 2.5% | 87.88M▲ 452.9% | 45.76M▼ 47.9% | 36.7M▼ 19.8% | 31.86M▼ 13.2% | 12.95M▲ 0% |
| Asset Turnover | - | - | - | - | 0.00x | - | - | - | 0.00x |
| Asset Growth % | - | 666.45% | -37.2% | 2.52% | 452.92% | -47.93% | -19.8% | -13.18% | -81.72% |
| Total Current Liabilities | 176.71K | 2.14M | 690.55K | 2.52M | 11.57M | 7.23M | 8.3M | 7.01M | 3.29M |
| Accounts Payable | 165.41K | 1.99M | 561.29K | 1.77M | 4.14M | 6.16M | 7.62M | 6.98M | 0 |
| Days Payables Outstanding | 1.13K | 7.93K | 1.76K | 3.59K | 8.67K | 13.86K | 14.85K | - | 61.42K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 37.21K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.3K | 153.89K | 0 | 0 | 6.66M | 1.04M | 238.18K | 0 | 3.25M |
| Current Ratio | 14.06x | 11.22x | 20.81x | 5.94x | 7.53x | 6.27x | 4.36x | 4.52x | 4.52x |
| Quick Ratio | 14.06x | 8.26x | 11.83x | 5.80x | 7.53x | 6.27x | 4.36x | 4.52x | 4.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 190.04K | 269.22K | 140.28K | 104.65K | 72.87K | 16.54K | 158.53K | 125.52K | 97.27K |
| Long-Term Debt | 190.04K | 269.22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 140.28K | 104.65K | 72.87K | 16.54K | 158.53K | 125.52K | 446.2K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 366.76K | 2.41M | 830.83K | 2.62M | 11.64M | 7.25M | 8.45M | 7.14M | 3.39M |
| Total Debt | 190.04K | 269.22K | 190.75K | 156.57K | 117.58K | 53.76K | 174.34K | 158.53K | 134.2K |
| Net Debt | -2.17M | -16.46M | -6.77M | -13.87M | -83.78M | -43.77M | -34.76M | -30.42M | -11.49M |
| Debt / Equity | 0.07x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.35x |
| Interest Coverage | -26.24x | -11.14x | -17543.88x | - | - | - | - | - | - |
| Total Equity | 2.85M▲ 0% | 22.27M▲ 680.5% | 14.67M▼ 34.1% | 13.27M▼ 9.6% | 76.24M▲ 474.5% | 38.51M▼ 49.5% | 28.25M▼ 26.6% | 24.73M▼ 12.5% | 9.56M▲ 0% |
| Equity Growth % | - | 680.47% | -34.13% | -9.55% | 474.5% | -49.49% | -26.65% | -12.45% | -56.25% |
| Book Value per Share | 0.13 | 0.92 | 0.57 | 0.44 | 1.76 | 0.62 | 0.44 | 0.35 | 0.11 |
| Total Shareholders' Equity | 2.85M | 22.27M | 14.67M | 13.27M | 76.24M | 38.51M | 28.25M | 24.73M | 9.56M |
| Common Stock | 4.26M | 36.72M | 39.41M | 51.92M | 142.92M | 108.84M | 148.52M | 179.34M | 187.36M |
| Retained Earnings | -1.66M | -17.55M | -31.24M | -51.88M | -83.52M | -84.43M | -142.58M | -179.25M | -205.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 259.46K | 1.85M | 1.73M | 4.46M | 4.18M | 2.6M | 3.52M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRDL Cash Flow Statement
Cardiol Therapeutics Inc. (CRDL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.29M | -10.89M | -11.38M | -9.13M | -23.55M | -27.22M | -25.18M | -25.06M | -25.06M |
| Operating CF Margin % | - | - | - | - | -37822.25% | - | - | - | - |
| Operating CF Growth % | - | -743.06% | -4.46% | 19.78% | -157.97% | -15.58% | 7.49% | 0.47% | 25.72% |
| Net Income | -1.66M | -15.89M | -13.68M | -20.64M | -31.64M | -30.93M | -28.13M | -36.68M | -32.29M |
| Depreciation & Amortization | 53.34K | 91.49K | 150.57K | 229.54K | 220.42K | 219.91K | 248.35K | 373.11K | 124.5K |
| Stock-Based Compensation | 237 | 1.65M | 3.27M | 2.77M | 8.5M | 5.01M | 4.16M | 14.28M | 10.83M |
| Deferred Taxes | 0 | 7.88M | 0 | 0 | -4.92M | -9.16M | 0 | 0 | 0 |
| Other Non-Cash Items | 267.01K | 574.86K | 507.74K | 201.02K | 4.21M | 1.89M | -911.39K | -2.1M | -1.28M |
| Working Capital Changes | 48.38K | -5.2M | -1.62M | 8.32M | 76.52K | 5.75M | -545.88K | -931.57K | 887.8K |
| Change in Receivables | -101.75K | -359.03K | -467.09K | 707.95K | -59.95K | -144.18K | 200.32K | -81.75K | 70.83K |
| Change in Inventory | 0 | -6.35K | 142.58K | 1.1M | 17.97K | -4.47M | 0 | 0 | 0 |
| Change in Payables | 176.71K | 1.96M | 467.09K | 0 | 2.39M | 4.47M | 0 | 0 | 0 |
| Cash from Investing | -29.17K | -13.79K | -424.31K | -40.6K | -12.92K | -74.71K | -64.31K | -21.29K | -27.55K |
| Capital Expenditures | -29.17K | -13.79K | -424.31K | -40.6K | -12.92K | -74.71K | -64.31K | -21.29K | -27.55K |
| CapEx % of Revenue | - | - | - | - | 20.74% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -7.23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.68M | 25.28M | 2.03M | 16.3M | 93.44M | -53.93K | -55.38K | 18.84M | 18.68M |
| Debt Issued (Net) | 400K | 12.07M | -20.19K | -50.47K | -51.92K | -53.93K | -55.38K | -41.53K | -55.38K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -120.55K | -1.02M | 382.15K | -904.51K | 9.41M | 0 | 0 | -2.47M | 18.74M |
| Net Change in Cash | 2.36M▲ 0% | 14.37M▲ 510.0% | -9.78M▼ 168.0% | 7.07M▲ 172.3% | 69.87M▲ 888.5% | -24.43M▼ 135.0% | -24.54M▼ 0.4% | -4.35M▲ 82.3% | -4.26M▲ 0% |
| Free Cash Flow | -1.32M▲ 0% | -10.91M▼ 725.5% | -11.8M▼ 8.2% | -9.17M▲ 22.3% | -23.56M▼ 157.0% | -27.3M▼ 15.8% | -25.24M▲ 7.5% | -25.08M▲ 0.6% | -24.25M▲ 0% |
| FCF Margin % | - | - | - | - | -37842.99% | - | - | - | - |
| FCF Growth % | - | -725.49% | -8.22% | 22.32% | -156.97% | -15.84% | 7.51% | 0.64% | 6.58% |
| FCF per Share | -0.06 | -0.45 | -0.46 | -0.31 | -0.55 | -0.44 | -0.39 | -0.35 | -0.35 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.69x | 1.08x | 0.56x | 0.94x | 1.19x | 1.19x | 0.68x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRDL Key Ratios
Cardiol Therapeutics Inc. (CRDL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -126.5% | -57.12% | -115.96% | -55.89% | -39.77% | -63.58% | -138.47% | -337.72% |
| Return on Invested Capital (ROIC) | -170.57% | -119.13% | -333.33% | - | - | - | - | 513.31% |
| Gross Margin | - | - | - | -179.87% | - | - | - | - |
| Net Margin | - | - | - | -40170.87% | - | - | - | - |
| Debt / Equity | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | -11.14x | -17543.88x | - | - | - | - | - | - |
| FCF Conversion | 0.69x | 1.08x | 0.56x | 0.94x | 1.19x | 1.19x | 0.68x | 0.75x |
| Revenue Growth | - | - | - | - | -100% | - | - | - |
CRDL Frequently Asked Questions
Cardiol Therapeutics Inc. (CRDL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cardiol Therapeutics Inc. (CRDL) grew revenue by 0.0% over the past year. Growth has been modest.
Cardiol Therapeutics Inc. (CRDL) reported a net loss of $32.3M for fiscal year 2024.
Dividend & Returns
Cardiol Therapeutics Inc. (CRDL) has a return on equity (ROE) of -138.5%. Negative ROE indicates the company is unprofitable.
Cardiol Therapeutics Inc. (CRDL) had negative free cash flow of $24.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More CRDL
Cardiol Therapeutics Inc. (CRDL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates